NCT02895568 is a clinical trial in Plasmodium Falciparum, sponsored by University of Oxford.

Who is sponsoring NCT02895568?

NCT02895568 is sponsored by University of Oxford.

What condition does NCT02895568 study?

NCT02895568 studies Plasmodium Falciparum.

Is NCT02895568 still recruiting?

NCT02895568 is currently completed. Last updated 7 April 2022.

Last reviewed 2022-04-07 · How we verify

NCT02895568

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers

Completed Last updated 7 April 2022

What this trial tests

trial in Plasmodium Falciparum in 399 participants. Completed in 6 September 2018.

Timeline

16 September 2016

Primary endpoint
6 September 2018

6 September 2018

Quick facts

Lead sponsor	University of Oxford
Status	Completed
Study type	OBSERVATIONAL
Enrollment	399
Start date	16 September 2016
Primary completion	6 September 2018
Estimated completion	6 September 2018
Sites	1 location across Chad

Conditions studied

Plasmodium Falciparum — all drugs for Plasmodium Falciparum →

Sponsor

University of Oxford

Who can join

Adults 6 Months to 75, any sex, with Plasmodium Falciparum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to measure prevalence of established and candidate molecular markers of drug resistant malaria at Komé, Doba, Republic of Chad.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Plasmodium Falciparum

Currently open trials in the same condition.

NCT06923592 — Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02895568 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 7 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02895568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing